Treatment-Emergent Cilgavimab Resistance Was Uncommon in Vaccinated Omicron BA.4/5 Outpatients

Mutations in the SARS-CoV-2 Spike glycoprotein can affect monoclonal antibody efficacy. Recent findings report the occurrence of resistant mutations in immunocompromised patients after tixagevimab/cilgavimab treatment. More recently, the Food and Drug Agency revoked the authorization for tixagevimab...

Descripción completa

Detalles Bibliográficos
Autores principales: Gruber, Cesare Ernesto Maria, Tucci, Fabio Giovanni, Rueca, Martina, Mazzotta, Valentina, Gramigna, Giulia, Vergori, Alessandra, Fabeni, Lavinia, Berno, Giulia, Giombini, Emanuela, Butera, Ornella, Focosi, Daniele, Prandi, Ingrid Guarnetti, Chillemi, Giovanni, Nicastri, Emanuele, Vaia, Francesco, Girardi, Enrico, Antinori, Andrea, Maggi, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605390/
https://www.ncbi.nlm.nih.gov/pubmed/37892220
http://dx.doi.org/10.3390/biom13101538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605390/
https://www.ncbi.nlm.nih.gov/pubmed/37892220
http://dx.doi.org/10.3390/biom13101538

Ejemplares similares